Jouvence Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Drug Discovery Tools; Genomics. Jouvence is dedicated to developing anti-aging therapies through genomics efforts. The company has licensed the LAG-1 gene, one of the first genes definitively linked to the longevity of an organism. Yeast strains in which the gene has been knocked out live 100% longer than average.
You may also be interested in...
The Emerging Science of Aging
New understanding of genetics and molecular medicine are behind companies targeting diseases of saging (the age when senescene begins)--some caused by geronto-genes.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.